Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neoadjuvant Treatment of Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
- Status
- UNKNOWN
- Phase
- PHASE4
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
- Status
- UNKNOWN
- Phase
- PHASE2
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Status
- RECRUITING
- Phase
- PHASE2
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
- Status
- COMPLETED
- Phase
- PHASE3